TRBV Gene Use Could Act as Biomarker in HER2+ Breast Cancer

Direct measurements of TRBV genes could provide a biomarker to predict response to dual HER2 blockade in women with HER2-positive breast cancer.

Source: CancerNetwork - June 26, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news